2014-06-26 12:57:19 UTC

Your GI Research May Create the Next New Drug

July 3, 2014

Apply by July 28 to be considered to work directly with an international pharmaceutical company and bring your research to life.

Are you interested in working with a commercial partner to bring your GI research to life?

Funded by Takeda Pharmaceuticals International, Inc. and the AGA Research Foundation, researchers are invited to submit a summary of their concept for collaboration that could yield a new drug or molecular diagnostic relevant to celiac disease or GI motility disorder (particularly those involving neural/ hormonal dysfunction or the gut microbiome). The deadline to submit an application is July 28, 2014.

The most promising will be invited to present their concepts in person at a private conference held at Takeda Pharmaceuticals International, Inc. headquarters near Chicago on Oct. 8, 2014, and may be chosen to work directly with this international company to further develop their promising ideas.

View additional details and apply at www.gastro.org/discovery.

More on Celiac Disease

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

APPs: Enhance your delivery of patient care

March 28, 2018

AGA's popular course for advanced practice providers will be held this summer in Chicago.

HLA-DQ–Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption

March 1, 2018

An HLA-DQ–gluten tetramer based assay that detects gluten-specific T cells accurately identifies patients with and without celiac disease, regardless of whether the individuals are on a gluten-free diet.